2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 1
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Lymphoid
1
Conditions
Sarcoma, Kaposi
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Epstein-Barr Virus Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
409
Cyclophosphamide
398
Carboplatin
307
Gemcitabine
286
Nivolumab
276
Paclitaxel
274
Cisplatin
252
Radiotherapy
225
Dexamethasone
209
Bevacizumab
207
fludarabine
195
Docetaxel
186
Rituximab
183
Capecitabine
171
Oxaliplatin
158
Lenalidomide
157
Fluorouracil
152
Temozolomide
138
Cytarabine
135
Etoposide
128
Irinotecan
124
Cetuximab
123
fludarabine phosphate
121
Injections
118
venetoclax
116
Ipilimumab
115
Doxorubicin
114
Azacitidine
108
130-nm albumin-bound paclitaxel
108
Pemetrexed
107
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02757326
2021-06-18
ABC-103
RedHill Biopharma Limited
Phase 1/2
Terminated
13 enrolled
12 charts
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn